Sun Pharma secures ex-US, ex-China rights to LIB Therapeutics’ PCSK9 cholesterol therapy
Sun Pharma has signed an exclusive licensing agreement with US-based LIB Therapeutics for lerodalcibep outside the US and China, opening access to the estimated $3.7 billion global PCSK9 cholesterol-treatment market.
The development
Sun Pharma signed an exclusive agreement with LIB Therapeutics on September 28 for Lerodalcibep rights outside the United States and China, gaining access to a $3.7 billion PCSK9 market.
The numbers
- September 28
- $3.7 billion
- 38 per cent
- $2.9 billion
- MAT Q2 2026
- September 21, 2026
- six months
Why it matters to operators and investors
The transaction shows Sun Pharma using targeted regional licensing to secure late-stage innovation while avoiding the cost and risk of acquiring global rights.
What to watch next
- Lerodalcibep pivotal-trial data, cardiovascular-outcomes evidence, and regulator interactions.
- Approval filings and decisions outside the US and China, especially in Europe, Japan, Canada, and selected emerging markets.
- Label details on dosing frequency, indicated patient population, LDL-C efficacy, immunogenicity, and safety.
- Net-price and reimbursement decisions relative to Repatha, Praluent, inclisiran, and emerging oral lipid-lowering therapies.
- Manufacturing-scale, supply-chain, and launch-readiness disclosures from LIB Therapeutics and Sun Pharma.
- Sun Pharma guidance on upfront payments, milestones, launch timing, and expected specialty-portfolio contribution.
- Prioritize regulatory and reimbursement sequencing in markets where Sun Pharma has established specialty infrastructure and premium biologics pricing.
- Build medical-affairs evidence around LDL-C lowering, cardiovascular-risk positioning, adherence, and differentiated dosing versus incumbent PCSK9 therapies.
- Secure biologics supply, cold-chain capacity, and local pharmacovigilance readiness well ahead of country launches.
- Develop payer value dossiers targeting statin-intolerant, familial hypercholesterolemia, and very-high-risk ASCVD populations.
- Evaluate partnership or co-promotion arrangements in European and other markets where Sun Pharma's cardiovascular commercialization scale is limited.
The counter-case
The addressable-market figure may overstate the opportunity: PCSK9 therapy is already competitive, with entrenched injectable brands, pricing pressure, payer restrictions, and growing interest in lower-cost alternatives. Sun Pharma is licensing rights rather than acquiring a proven commercial asset, so value depends on regulatory approvals, launch execution across fragmented international markets, reimbursement, and LIB Therapeutics’ ability to generate durable clinical and manufacturing evidence. A long-acting or differentiated profile may not be sufficient if treatment cost, adherence advantages, or cardiovascular-outcomes data do not clearly beat existing options.